Rugge Massimo, Buja Alessandra, Tropea Saveria, Girardi Giovanni, Franzese Luigi Cosenza, Cozzolino Claudia, Zorzi Manuel, Vecchiato Antonella, Del Fiore Paolo, Brunello Antonella, Brazzale Alessandra Rosalba, Baldo Vincenzo, Dei Tos Angelo Paolo, Rossi Carlo Riccardo, Mocellin Simone
Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padua, 35121 Padua, Italy.
Veneto Tumor Registry, Azienda Zero, 35132 Padua, Italy.
Cancers (Basel). 2022 Jun 24;14(13):3109. doi: 10.3390/cancers14133109.
The clinical treatment of soft tissue sarcoma (STS) has evolved substantially over the last decade. This population-based cohort study based on real-world data included all incidental STS recorded by the Veneto Cancer Registry in 2017. Data on hospital admissions, emergency department and outpatient visits, drug prescriptions, and use of medical devices within two years from STS diagnosis were obtained from administrative databases. The average per-patient real-world costs over this two-year period, in total and by single expenditure item, were calculated and stratified by stage of disease at diagnosis, tumor histology and tumor site. The mean total cost per patient amounted to EUR 16,793. A higher TNM stage at diagnosis was associated with higher healthcare costs, as follows: compared with stage I, the average total cost per patient was 1.32, 2.18 and 3.36 times greater for stages II, III and IV, respectively. Hospital stays generated the greatest costs (averaging EUR 7950 per patient), followed by outpatient visits (mean EUR 3947 per patient) and drug prescriptions (mean EUR 3664 per patient). Given the paucity of population-based studies, the present results can serve as a reference for further cost-effectiveness analyses on care strategies for patients with STS.
在过去十年中，软组织肉瘤（STS）的临床治疗有了显著进展。这项基于真实世界数据的人群队列研究纳入了威尼托癌症登记处2017年记录的所有偶发性STS病例。从行政数据库中获取了STS诊断后两年内的住院、急诊科和门诊就诊、药物处方以及医疗设备使用的数据。计算了这两年期间每位患者的平均真实世界成本，包括总计和按单项支出项目计算，并按诊断时的疾病阶段、肿瘤组织学和肿瘤部位进行分层。每位患者的平均总成本为16,793欧元。诊断时较高的TNM分期与较高的医疗成本相关，具体如下：与I期相比，II期、III期和IV期每位患者的平均总成本分别高出1.32倍、2.18倍和3.36倍。住院产生的费用最高（每位患者平均7950欧元），其次是门诊就诊（每位患者平均3947欧元）和药物处方（每位患者平均3664欧元）。鉴于基于人群的研究较少，本研究结果可为进一步分析STS患者护理策略的成本效益提供参考。
